R&D News | pharmaphorum

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

News

Pharma says UK is 'tumbling down' rankings for investment

The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

News

Fresh blow to UK life sciences as MSD abandons £1bn project

In a blow to UK life science ambitions, MSD has scrapped a £1bn expansion of its operations in the country, saying it does not value innovation.

News

Lilly offers AI discovery models to biotech partners

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.

News

Lilly eyes earlier use of blood cancer drug Jaypirca

Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

Pharma says UK is 'tumbling down' rankings for investment

Fresh blow to UK life sciences as MSD abandons £1bn project

Lilly offers AI discovery models to biotech partners

Lilly eyes earlier use of blood cancer drug Jaypirca

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks